CorDynamics Revenue and Competitors
Estimated Revenue & Valuation
- CorDynamics's estimated annual revenue is currently $4.3M per year.
- CorDynamics's estimated revenue per employee is $155,000
Employee Data
- CorDynamics has 28 Employees.
- CorDynamics grew their employee count by 4% last year.
CorDynamics's People
Name | Title | Email/Phone |
---|
CorDynamics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $2.8M | 18 | -14% | N/A | N/A |
#2 | $0.8M | 5 | 0% | N/A | N/A |
#3 | $2M | 13 | 0% | N/A | N/A |
#4 | $707.3M | 2852 | 14% | $1.1B | N/A |
#5 | $1.7M | 11 | 0% | N/A | N/A |
#6 | $32.6M | 210 | 6% | N/A | N/A |
#7 | $2.6M | 17 | 6% | N/A | N/A |
#8 | $1.1M | 7 | -30% | N/A | N/A |
#9 | $1.4M | 9 | -10% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is CorDynamics?
CorDynamics is a contract research laboratory and consulting group specializing in customized cardiovascular preclinical drug discovery and safety studies. Experts in cardiovascular models ranging from the Langendorff isolated heart, through anesthetized and telemetry subjects, CorDynamics can create nearly any experimental scenario for lead optimization with drug screening as well as regulatory GLP-compliant studies. Our drug discovery assessments investigate for: • thrombosis • heart failure • arrhythmogenesis • ischemia reperfusion • atrial fibrillation • pulmonary hypertension We’ve worked in the pharmaceutical industry. We understand the unpredictability of drug development. Providing dynamic cardiovascular drug discovery and safety research with unparalleled customer service is the heartbeat of our business.
keywords:N/AN/A
Total Funding
28
Number of Employees
$4.3M
Revenue (est)
4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.4M | 28 | -18% | N/A |
#2 | $3.8M | 28 | 65% | $134.8M |
#3 | $3.1M | 28 | -3% | N/A |
#4 | $2.8M | 28 | 4% | N/A |
#5 | $3.2M | 28 | -18% | N/A |